About This Dossier

What This Site Is

BPC-157 Safe is a curated safety dossier — a close reading of the peer-reviewed toxicology and pharmacology record for BPC-157 (Body Protection Compound 157, pentadecapeptide GEPPPGKPADDAGLV), assembled study by study. No consultation, prescription, or diagnosis is offered here, and no one behind these pages practices medicine. Nothing on the site is for sale, supplied, or shipped; the compound is a subject of study, never a product on offer. What the pages hold is a sourced account of what the published studies measured, with every figure traced to its citation.

The domain name carries the modifier 'safe' because the preclinical toxicology record for BPC-157 is — by the standards of that record — unusually quiet: an LD1 not achieved at 2 g/kg in mice, a 28-day rat NOAEL at or above 4 mg/kg/day, a dog NOAEL at or above 10 mg/kg, negative genotoxicity, negative teratogenicity, zero adverse events in three published human pilot studies. That is the record the site documents. 'Safe' in the domain name is an editorial characterization of the preclinical dossier — not a claim about human safety, not a regulatory finding, not a product claim. The distinction matters and is made explicit here.

The site does not sell BPC-157. It carries no tie to any vendor, manufacturer, compounding pharmacy, clinic, or research institution. It is a maison's reading of the published literature — considered, cited, and answerable to the record alone, not a vendor's claims.

Editorial Standards and Sourcing Methodology

Every quantitative claim in this dossier cites a specific published study from the peer-reviewed literature — identified by journal, year, authors, and DOI. No claim has been extrapolated beyond what the cited study supports. Where the published record contains uncertainty — the concentration of authorship in the Zagreb group, the absence of large-scale randomized controlled trials, the theoretical angiogenesis-in-occult-malignancies concern raised by Jozwiak et al. — the dossier records those uncertainties explicitly.

The sources used are indexed in PubMed or PubMed Central. Journals cited include Pharmaceuticals (Basel), Frontiers in Pharmacology, Current Reviews in Musculoskeletal Medicine, HSS Journal, Life Sciences, Medicina (Kaunas), Journal of Orthopaedic Research, Biomedicines, International Journal of Molecular Sciences, Alternative Therapies in Health and Medicine, and Current Pharmaceutical Design. Every reference is available in the dossier's references page with DOI and PubMed link.

The voice of this site is the maison editorial register — composed, considered, materially restrained. The 'safe' modifier is rendered as composure rather than reassurance because the evidence warrants composure, not alarm and not hyperbole. The preclinical record is what it is: unusually quiet by the standards of the literature. The regulatory record is what it is: unapproved. Both are documented here, in the same register, with equal care.

Regulatory and Legal Posture

BPC-157 is not approved for human use by the FDA or any major regulatory agency as of 2025. Selling or marketing it as a drug, food, or dietary supplement for human consumption is not legally permitted in the United States. Athletes in sports governed by WADA-compliant anti-doping rules are prohibited from using it under S0 Non-Approved Substances — regardless of whether any adverse event has been documented.

This site does not advocate for any particular regulatory outcome. It documents what the published research shows and what the current regulatory framework provides. Those are different categories of information and they are kept distinct throughout this dossier.